SCHEMBL2809463

SCHEMBL2809463

CC(C)=NOCc1nc2c(N)nc3ccccc3c2s1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 19/20 0.63
TLR7 Q9NYK1 16/20 0.63
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809369 0.84 TLR8 (0.44) TLR8TLR7
SCHEMBL13128108 0.82 TLR8 (0.68) TLR8TLR7
SCHEMBL1527927 0.82 TLR8 (0.72) TLR8TLR7
SCHEMBL2808735 0.82 TLR8 (0.72) TLR8TLR7
SCHEMBL2810620 0.82 TLR8 (0.64) TLR8TLR7
Hydrochloric Acid SCHEMBL2807427 0.81 TLR8 (0.70) TLR8TLR7
SCHEMBL1528088 0.80 TLR8 (0.73) TLR8TLR7
SCHEMBL5767961 0.80 TLR8 (0.73) TLR8TLR7
SCHEMBL1528044 0.78 TLR8 (0.74) TLR8TLR7
SCHEMBL1528137 0.78 TLR8 (1.00) TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed
EP-1877056-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLOÝ4,5-C¨RING COMPOUNDS AND METHODS Coley Pharmaceutical Group, Inc. (US) 2008-01-16 EP disclosed
WO-2007120121-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-25 WO disclosed
WO-2007120121-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods IL4, IL2, TH TLR8 203/4885TLR7 43/4885GAA 3340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.